17. March 2015: Rep. Tom Price, R-Ga. the house budget announces during a press conference on Capitol Hill in Washington.
President-elect Donald Trump’s pick to run the health and Human Services Department traded more than 300,000 $in stocks of health-related companies in the past four years, while the sponsorship and support of legislation that potentially impact on this company’s shares.
Rep. Tom Price, R-Ga., bought and sold stock in over 40 health-care, pharmaceutical and biomedical companies since 2012, including a dozen in the current congressional session, according to a Wall Street Journal review of hundreds of pages of the stock-trade, he at the Congress.
In the same two-year period, he has sponsored and co-sponsored by 35 health-related bills in the house.
Its shares trade include Amgen, Bristol-Meyers Squibb, Eli Lilly, Pfizer and Aetna.
His largest single stock purchase was a August 2016 purchase of between $50,000 and $100,000 from an Australian biomedical company, Innate immune therapeutics, whose largest shareholder is a GOP Congresswoman on the trump-transition team, according to the applications, the list of price classes. The stock has since doubled in price.
Click for more from the Wall Street Journal